Baxter Healthcare Corp. recalls remaining heparin lots.
The Food & Drug Administration has issued a Public Health Update to inform the public that Baxter Healthcare Corp. has extended its recall in addition to heparin sodium injection 5,000 units/ml (10 ml multi-dose vials), 10,000 units/ml (4 ml multi-dose vials), 1,000 USP units/ml (single-dose vials), 5,000 USP units/ml (single-dose vials), and 10,000 USP units/ml (single-dose vials), and all HEP-LOCK and HEP-LOCK U/P, 10 USP units/ml and 100 USP units/ml vials, both preserved and preservative-free. The only heparin products from Baxter that will remain on the market are the large-volume parenterals, heparin sodium in 5% dextrose injection and heparin sodium in 0.9% sodium chloride injection. The recall was originally issued after an unusually higher number of allergic-like adverse patient reactions were reported. Nearly all the reported reactions have occurred in three specific areas of product use - renal dialysis, invasive cardiovascular procedures, and apheresis procedures. Among the reactions experienced were nausea, vomiting, chest pain, dizziness, fainting, and shortness of breath, including a potentially severe or life-threatening refractory hypotension. Pharmacies should segregate affected lots from their inventory and contact Baxter at 1-(800)-4-BAXTER to arrange for return and replacement product. Pharmacies that purchased the heparin indirectly should contact their wholesaler or distributor for return and replacement.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.